Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

57 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-11-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the skin toxicities in patients with epidermoid cancer, treated by Radiotherapy in association with Cetuximab.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiation Plus Cetuximab in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00115518

Carcinoma, Non-Small-Cell Lung

COMPLETED PHASE2

Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease

NCT02843165

Metastatic Cancer

COMPLETED PHASE2

Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer

NCT03408665

Liver Cancer Liver Metastases

ACTIVE_NOT_RECRUITING NA

Trial Comparing Two Protocols of re Irradiation in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract

NCT01211938

Squamous Cell Carcinoma

COMPLETED PHASE2/PHASE3

Adaptative Radiotherapy for Locally Advanced Cervical Cancer

NCT02937948

Uterine Cervical Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epidermoid Head and Neck Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patient with epidermoid cancer

receiving Cetuximab and radiotherapy

Cetuximab

Intervention Type DRUG

First cycle: 400 mg/m2 Next cycles: 250 mg/m2

Radiotherapy

Intervention Type RADIATION

Curative dose: 66 to 70 Gy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cetuximab

First cycle: 400 mg/m2 Next cycles: 250 mg/m2

Intervention Type DRUG

Radiotherapy

Curative dose: 66 to 70 Gy

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18 years
* Epidermoid head and neck carcinoma locally advanced
* Indication of Cetuximab and radiotherapy
* Karnofsky \>= 60
* Patients participating to another compatible study could be included after consultation with the study director Patients could be beforehand treated for an other ORL cancer

The radiotherapy will be delivered for curative aim (minimal dose 66 Gy)